
RealRate

PHARMACEUTICAL 2020

Teligent Inc. Rank 108 of 362





PHARMACEUTICAL 2020

Teligent Inc. Rank 108 of 362

The relative strengths and weaknesses of Teligent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Teligent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 153% points. The greatest weakness of Teligent Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -51%, being 252% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	61,644
Cost of Goods Sold	42,373
Intangible Assets	45,136
Liabilities, Current	16,606
Liabilities, Non-Current	2,256
Other Assets	3,776
Other Compr. Net Income	292
Other Expenses	276
Other Liabilities	193,350
Other Net Income	-16,828
Property and Equipment	96,349
Research and Development	10,758
Revenues	65,896
Selling, General and Administrative Expense	20,785

Output Variable	Value in 1000 USD
Assets	206,905
Liabilities	212,212
Expenses	74,192
Stockholders Equity	-5,307
Net Income	-25,124
Comprehensive Net Income	-24,978
Economic Capital Ratio	-51%